摘要: In this issue of Blood, Petersdorf et al report negative results the phase 3 study designed by Southwest Oncology Group (SWOG), which tested addition gemtuzumab ozogamicin (GO) to a 317 regimen in randomized fashion adult patients newly diagnosed with acute myeloid leukemia (AML) who are younger than 60 years. Also Rowe and Lowenberg discuss context 4 other controlled studies (1 1 positive predefined subset patients, 2 positive) performed during same period Europe.
ashpublications.org
bloodjournal.org参考文章(6)
Stephen H. Petersdorf, Kenneth J. Kopecky, Marilyn Slovak, Cheryl Willman, Thomas Nevill, Joseph Brandwein, Richard A. Larson, Harry P. Erba, Patrick J. Stiff, Robert K. Stuart, Roland B. Walter, Martin S. Tallman, Leif Stenke, Frederick R. Appelbaum, A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. ,vol. 121, pp. 4854- 4860 ,(2013) , 10.1182/BLOOD-2013-01-466706
A-L Taksin, O Legrand, E Raffoux, T de Revel, X Thomas, N Contentin, R Bouabdallah, C Pautas, P Turlure, O Reman, C Gardin, B Varet, S de Botton, F Pousset, H Farhat, S Chevret, H Dombret, S Castaigne, High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group Leukemia. ,vol. 21, pp. 66- 71 ,(2007) , 10.1038/SJ.LEU.2404434
William J Kell, Alan K Burnett, Raj Chopra, John AL Yin, Richard E Clark, Ama Rohatiner, Dominic Culligan, Ann Hunter, Archie G Prentice, Donald W Milligan, A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. ,vol. 102, pp. 4277- 4283 ,(2003) , 10.1182/BLOOD-2003-05-1620
Anjali Advani, Bertrand Coiffier, Myron S. Czuczman, Martin Dreyling, James Foran, Eva Gine, Christian Gisselbrecht, Nicolas Ketterer, Sunita Nasta, Ama Rohatiner, Ingo G.H. Schmidt-Wolf, Martin Schuler, Jorge Sierra, Mitchell R. Smith, Gregor Verhoef, Jane N. Winter, Joseph Boni, Erik Vandendries, Mark Shapiro, Luis Fayad, Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study Journal of Clinical Oncology. ,vol. 28, pp. 2085- 2093 ,(2010) , 10.1200/JCO.2009.25.1900
Sylvie Castaigne, Cécile Pautas, Christine Terré, Emmanuel Raffoux, Dominique Bordessoule, Jean-Noel Bastie, Ollivier Legrand, Xavier Thomas, Pascal Turlure, Oumedaly Reman, Thierry de Revel, Lauris Gastaud, Noémie de Gunzburg, Nathalie Contentin, Estelle Henry, Jean-Pierre Marolleau, Ahmad Aljijakli, Philippe Rousselot, Pierre Fenaux, Claude Preudhomme, Sylvie Chevret, Hervé Dombret, Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study The Lancet. ,vol. 379, pp. 1508- 1516 ,(2012) , 10.1016/S0140-6736(12)60485-1
Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Jonathan Kell, Sylvie Freeman, Lars Kjeldsen, Ann E. Hunter, John Yin, Charles F. Craddock, Inge Hoegh Dufva, Keith Wheatley, Donald Milligan, Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia Journal of Clinical Oncology. ,vol. 30, pp. 3924- 3931 ,(2012) , 10.1200/JCO.2012.42.2964